Does the Alaunos Therapeutics (TCRT) Form 4 show any insider share sales by Jaime Vieser?

The filing does not report any insider sales. It records a grant of 6,515 common shares to Vieser and two holding entries for existing indirect positions, with no sale transactions or disposition codes such as open-market sales or tax-withholding transfers.

Alaunos Therapeutics (TCRT) director awarded 6,515 shares at $2.59

Q: What insider transaction did Alaunos Therapeutics (TCRT) director Jaime Vieser report?

Director Jaime Vieser reported receiving a share grant. He was awarded 6,515 shares of Alaunos Therapeutics common stock at $2.59 per share, recorded as a compensation-related acquisition rather than an open-market purchase or sale, increasing his directly held position to 38,853 shares.

Q: How many Alaunos Therapeutics (TCRT) shares does Jaime Vieser hold after this Form 4 filing?

After the grant, Vieser directly holds 38,853 shares. The filing also shows 13,503 shares held indirectly through Brushwood LLC, where he serves as manager, and 2,100 shares held indirectly for his children, reflecting both direct and indirect ownership interests.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics director Jaime Vieser reported an equity award. Vieser received a grant of 6,515 shares of Alaunos Therapeutics common stock at a price of $2.59 per share, increasing his directly held stake to 38,853 shares.

In addition to these direct holdings, the filing lists 13,503 shares held indirectly through Brushwood LLC, where Vieser is the manager, and 2,100 shares held indirectly for the benefit of his children.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Vieser Jaime

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,515	$2.59	$17K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 38,853 shares (Direct, null); Common Stock — 2,100 shares (Indirect, by Reporter's children)

Footnotes (1)

[object Object]

Key Figures

Share grant size: 6,515 shares Grant price: $2.59 per share Direct holdings after grant: 38,853 shares +2 more

5 metrics

Share grant size 6,515 shares Common stock grant to director Jaime Vieser

Grant price $2.59 per share Price for 6,515-share award of common stock

Direct holdings after grant 38,853 shares Common stock directly owned by Vieser after award

Indirect holdings via Brushwood LLC 13,503 shares Common stock held by Brushwood LLC, managed by Vieser

Indirect holdings for children 2,100 shares Common stock held indirectly for reporter's children

Key Terms

Grant, award, or other acquisition, Common Stock, indirect, Brushwood LLC

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect financial

"ownership_type: indirect"

Brushwood LLC financial

"nature_of_ownership: By Brushwood LLC"

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vieser Jaime

(Last)

(First)

(Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE

FLORIDA

33301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/29/2026		A		6,515	A	$2.59	38,853	D
Common Stock								2,100	I	by Reporter's children
Common Stock								13,503⁽¹⁾	I	By Brushwood LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.

Remarks:

1. Represents shares of common stock issued in lieu of board fees.

	/s/ Vieser, Jaime	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) director Jaime Vieser report?

Director Jaime Vieser reported receiving a share grant. He was awarded 6,515 shares of Alaunos Therapeutics common stock at $2.59 per share, recorded as a compensation-related acquisition rather than an open-market purchase or sale, increasing his directly held position to 38,853 shares.

How many Alaunos Therapeutics (TCRT) shares does Jaime Vieser hold after this Form 4 filing?

After the grant, Vieser directly holds 38,853 shares. The filing also shows 13,503 shares held indirectly through Brushwood LLC, where he serves as manager, and 2,100 shares held indirectly for his children, reflecting both direct and indirect ownership interests.

What does the $2.59 price in the Alaunos Therapeutics (TCRT) Form 4 represent?

The $2.59 figure is the grant price for the awarded shares. Vieser received 6,515 shares of Alaunos Therapeutics common stock at $2.59 per share as a grant, classified as a non-derivative, compensation-related acquisition rather than a market trade.

How are Brushwood LLC holdings treated in the Alaunos Therapeutics (TCRT) Form 4?

Brushwood LLC’s holdings are reported as indirect ownership. The filing lists 13,503 Alaunos shares held by Brushwood LLC, with a footnote stating Vieser is the manager of the LLC, so these shares are attributed as indirectly owned rather than part of his direct position.